Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 7/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 5/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.82 |
| ▸ | THRB | P10828 | 7/20 | 0.82 |
| ▸ | BLM | P54132 | 7/20 | 0.82 |
| ▸ | RECQL | P46063 | 6/20 | 0.82 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.82 |
| ▸ | TOP2A | P11388 | 5/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.82 |
| ▸ | MAPT | P10636 | 4/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648501 | 1.00 | S100A4 (1.00) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL31237243 | 0.99 | S100A4 (0.99) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL17514312 | 0.94 | S100A4 (0.90) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL28160200 | 0.94 | S100A4 (0.89) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL31238308 | 0.93 | S100A4 (0.86) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL7805182 | 0.93 | S100A4 (0.86) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL29338082 | 0.92 | S100A4 (1.00) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL8639928 | 0.92 | S100A4 (1.00) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL3036863 | 0.92 | S100A4 (0.86) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL29132019 | 0.92 | S100A4 (0.85) | S100A4PAX8HSP90AA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110076318-A1 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED MATTERS | ALLERGAN, INC. | 2011-03-31 | — | — | US | disclosed |
| US-20090163550-A1 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS | ALLERGAN, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1765284-A1 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR DRUG DELIVERY SYSTEMS AND RELATED METHODS OF MANUFACTURING | Allergan, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20050271705-A1 | Retinoid-containing sustained release intraocular drug delivery system and related methods | ALLERGAN, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| WO-2005107707-A1 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR DRUG DELIVERY SYSTEMS AND RELATED METHODS OF MANUFACTURING | ALLERGAN, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-0345598-B1 | Anthracycline derivatives with a cytostatic activity | BEHRINGWERKE AG (DE) | 1998-08-12 | — | — | EP | disclosed |
| US-5260425-A | Anthracycline derivatives having cytostatic activity | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1993-11-09 | — | — | US | disclosed |
| EP-0345598-A2 | Anthracycline derivatives with a cytostatic activity | BEHRINGWERKE Aktiengesellschaft (DE) | 1989-12-13 | — | — | EP | disclosed |
| US-4202967-A | ANTITUMOR | SRI INTERNATIONAL (US) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076318-A1 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED MATTERS | RARG, RARB, RARA | S100A4 3499/4885PAX8 75/4885HSP90AA1 1241/4885 |
| US-20090163550-A1 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS | RARB, RARG, RARA | S100A4 3545/4885PAX8 76/4885HSP90AA1 714/4885 |
| US-20050271705-A1 | Retinoid-containing sustained release intraocular drug delivery system and related methods | RARB, RARG, RARA | S100A4 4100/4885PAX8 98/4885HSP90AA1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.